HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.


Related Content

Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA
FDA Broadens Nicotine Therapy Indication Review With Steering Committee Docket
Trump's Budget Surprise: FDA Gains 13% Increase
Senate OTC Monograph Bill Boosts Industry Hopes For Passage This Year
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
Making Nutritionals Eligible For Health Savings Accounts Whets Congress' Appetite
OTC Switch Interest Cooled By Study Costs To Update Safety Data
FDA Floats OTC Monograph Overhaul To Be “More Agile And Responsive”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts